Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Wednesday, December 12, 2018

Senotherapeutics: emerging strategy for healthy aging and age-related disease.

Related Articles

Senotherapeutics: emerging strategy for healthy aging and age-related disease.

BMB Rep. 2018 Dec 11;:

Authors: Kim EC, Kim JR

Abstract
Cellular senescence (CS) is one of hallmarks of aging and accumulation of senescent cells (SCs) with age contributes to tissue or organismal aging, as well as the pathophysiologies of diverse age-related diseases (ARDs). Genetic ablation of SCs in tissues lengthened health span and reduced the risk of age-related pathologies in a mouse model, suggesting a direct link between SCs, longevity, and ARDs. Therefore, senotherapeutics, medicines targeting SCs, might be an emerging strategy for the extension of health span, and prevention or treatment of ARDs. Senotherapeutics are classified as senolytics which kills SCs selectively; senomorphics which modulate functions and morphology of SCs to those of young cells, or delays the progression of young cells to SCs in tissues; and immune-system mediators of the clearance of SCs. Some senolytics and senomorphics have been proven to markedly prevent or treat ARDs in animal models. This review will present the current status of the development of senotherapeutics, in relation to aging itself and ARDs. Finally, future directions and opportunities for senotherapeutics use will discussed. This knowledge will provide information that can be used to develop novel senotherapeutics for health span and ARDs.

PMID: 30526770 [PubMed - as supplied by publisher]



from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2QupfgQ

No comments:

Post a Comment